

Press Briefing Schedule At-a-Glance

All press briefings are EMBARGOED; all in-person Press Briefings are located in McCormick Place, Lakeside Building E353a

Monday, May 18 Pre-Meeting Briefing on Regular Abstracts	Tuesday, May 26 Pre-Meeting Briefing on LBAs	Saturday, May 30 On-Site Briefing on LBAs Released Sunday	Sunday, May 31 On-Site Briefing on LBAs Released Monday/Tuesday	Monday, June 1 On-Site Briefing: Breakthrough & Bites
<p>Embargo on all abstracts lifts Thursday, May 21 at 5:00 PM (ET)</p> <p>Press Briefing Time: 5:30-7:00 PM (ET) <i>Virtual event conducted via Zoom webinar</i></p> <p>5517 (Marchetti): Effects of short-term fasting compared to free diet in ovarian cancer patients: Results from a two-arm pilot randomized trial.</p> <p>3143 (Orland): Can GLP-1 receptor agonists mitigate cancer progression?: A propensity-matched analysis across seven solid tumors.</p> <p>12004 (Choi): YOCAS yoga, mood disturbance, and insomnia: A URCC NCORP RB nationwide, phase III, randomized, controlled trial with cancer survivors.</p> <p>12010 (Ligibel): Effect of a weight loss intervention (WLI) on quality of life (QOL) and symptoms in women with breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.</p> <p>5005 (Morgans): Cognitive effects of darolutamide vs enzalutamide: Results of ARACOG (AFT-47), a randomized clinical trial from the Alliance for Clinical Trials in Oncology.</p>	<p>Embargo on all abstracts lifts Saturday, May 30 at 7:00 AM (CT)/8:00 AM (ET)</p> <p>Press Briefing Time: 3:30-5:00 PM (ET) <i>Virtual event conducted via Zoom webinar</i></p> <p>LBA503 (de Boniface): Omission of completion axillary dissection in patients with breast cancer and sentinel lymph node macrometastases: Overall survival and patient-reported arm morbidity from the randomized SENOMAC trial.</p> <p>LBA100 (Swanton): NHS-Galleri: Primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection (MCED) test in population screening.</p> <p>LBA7000 (Lenz): frontMIND: Phase 3 study of tafasitamab (Tafa) plus lenalidomide (Len) and R-CHOP for patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL).</p> <p>LBA2000 (Weinberg): Final results of a randomized, controlled, phase 3 trial comparing resection and post-operative stereotactic radiation versus resection and cesium-131 tile-based radiation for treatment of newly diagnosed brain metastases.</p>	<p>Embargo on all abstracts lifts Sunday, May 31 at 7:00 AM (CT)/8:00 AM (ET)</p> <p>Press Briefing Time: 8:00-9:30 AM (CT) <i>In-person and available virtually via Zoom</i></p> <p>LBA1 (Taplin): Final analysis of PROTEUS, a phase 3 randomized, double-blind, placebo (PBO)–controlled study of perioperative (neoadjuvant and adjuvant) apalutamide (APA) plus androgen deprivation therapy (ADT) versus ADT with radical prostatectomy (RP) in men with high-risk localized prostate cancer (HRLPC).</p> <p>LBA2 (Dickson): SARCO41: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.</p> <p>LBA3 (Goldman): Event-Free Survival with Adjuvant Selpercatinib in Stage IB-IIIa RET Fusion-Positive NSCLC: Primary Results of the Phase 3 LIBRETTO-432 Trial</p> <p>LBA4 (Lu): Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: Overall survival results of the phase 3 HARMONI-6 trial</p> <p>LBA5 (Wolpin): Daraxonrasib, a RAS(ON) multi-selective inhibitor, vs chemotherapy in previously treated patients with metastatic pancreatic adenocarcinoma (mPDAC): Primary analysis from the phase 3 RASolute 302 study.</p> <p>LBA6007 (Shah): Ultra-Low-Dose Immunotherapy Plus Oral Metronomic Chemotherapy Versus Paclitaxel-Carboplatin in Platinum-Sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Randomized Phase III Trial.</p>	<p>Press Briefing Time: 8:00-9:30 AM (CT) <i>In-person and available virtually via Zoom</i></p> <p>LBA12008 (Chan): SUPPORT+ digital self-management and clinical support for advanced cancer: A randomized controlled trial. Embargo lifts Monday, June 1 at 7:00 AM (CT)/8:00 AM (ET)</p> <p>LBA4000 (Abou-Alfa): Efficacy and safety results from EMERALD-3: A phase 3, randomized study of tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization (TACE) in participants (pts) with embolization-eligible unresectable hepatocellular carcinoma (HCC). Embargo lifts Monday, June 1 at 7:00 AM (CT)/8:00 AM (ET)</p> <p>LBA1000 (Kalinsky): Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-04 study of participants (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs chemotherapy (chemo) plus pembro. Embargo lifts Tuesday, June 2 at 7:00 AM (CT)/8:00 AM (ET)</p>	<p><i>Special event to announce the official Press Program for the 2026 ASCO Breakthrough Meeting.</i></p>